News archive

Breast cancer is the most common cancer among women and the likelihood of surviving the disease is higher if the cancer is detected early and the tumour is relatively small and not very aggressive.

Breast cancer is the most common cancer affecting women and many women are being treated to prevent the cancer from returning, for example with adjuvant hormone therapy. This therapy is prescribed as a once-a-day pill for estrogen receptor-positive breast cancer patients (around 80% of all cases) for a duration of at least five years.

While there are currently a dozen approved AI systems for breast cancer screening, it has been difficult to evaluate their clinical performance objectively. Now, however, there is a Swedish validation platform ready to compare how well AI systems detect signs of breast cancer – and its development has been led by researchers at Karolinska Institutet.

Researchers at Karolinska Institutet have developed a method that should be able to predict whether a patient with breast cancer will benefit from a particular treatment or not. The cell-based method has been tested on patients with promising results, according to a study published in PNAS.

Breast cancer is the most common cancer type in women globally, but there is a continuous decline in mortality rates. A partial explanation for this may be that effective treatments are being developed for subgroups of breast cancer patients. It is still challenging to optimise treatment plans for every individual.

Two researchers at Karolinska Institutet have been awarded the Athena prize for an AI-based image analysis in precision medicine for risk classification of breast cancer patients. The Athena Prize is Sweden's largest prize for research and innovations that have been produced through collaboration between healthcare, academia and industry.

Women with a breast cancer diagnosis undergoing procedures for fertility preservation are not at increased risk of recurrence of the disease or disease-specific mortality. This has been shown in a study by Karolinska Institutet that followed the participants for five years on average. The results, published in the journal JAMA Oncology, could in the future provide safety and new hope to women who want to preserve their fertility after cancer treatment with chemotherapy.

To investigate the long-term benefit of hormone-lowering treatment, researchers at Karolinska Institutet have done a 20-year follow-up of premenopausal women with breast cancer. The study, published in the Journal of Clinical Oncology, indicates that the treatment provides protection even after a longer period of time and that different patients seem to benefit from different hormonal treatments.

In a new thesis, Rickard Strandberg, PhD student at the Department of Medical Epidemiology and Biostatistics, lays the foundations for a new natural history model for breast cancer. By taking advantage of available detailed screening cohorts, Rickard’s work includes three diverse applications of this model.

Researchers at Karolinska Institutet have identified a protein that protects against breast tumour growth and that can be linked to a better prognosis in breast cancer patients. The results, which are published in the journal Nature Communications, may contribute to the development of new therapies for difficult-to-treat forms of breast cancer.

An international team of scientists, including from Karolinska Institutet, has discovered a means of identifying the risk of breast and ovarian cancer by analysing cell samples from the cervix. By measuring epigenetic changes in cervical samples from over a thousand women, the researchers have found two unique signatures for breast and ovarian cancer. The results are presented in two papers in the journal Nature Communications.

79 KI researchers have received a total of SEK 254,450,000 in grants from the Swedish Cancer Society. In addition, four Fellowship prevention grants were also awarded to researchers at KI. In total, the Swedish Cancer Society distributed SEK 850 million, which is the largest amount ever.

The Breast Cancer Association's award 2021 goes to chief physician and KI professor Per Hall. He is recognized for his broad research on how breast cancer can be prevented and detected early with refined and individual methods.

Congratulations to five researchers at the Department of Molecular Medicine and Surgery who received funding from the Swedish Research Council within the field Medicine and Health at the dividend on October 28, 2021.

Researchers at Karolinska Institutet have developed an AI-based tool that improves the diagnosis of breast cancer tumours and the ability to predict the risk of recurrence. The greater diagnostic precision can lead to more personalised treatment for the large group of breast cancer patients with intermediate risk tumours. The results are published in the scientific journal Annals of Oncology.

A study involving researchers at Karolinska Institutet and University of Gothenburg has found that low levels of a protein called PDGFRb are associated with particularly good results of radiotherapy in women with early-stage breast cancer. The study, which is published in the journal Clinical Cancer Research, also suggests that the efficacy of radiotherapy can be improved with drugs that block this protein.

While the drug tamoxifen reduces the risk of developing breast cancer and prevents recurrence, the side-effects cause many women to discontinue their treatment. A study involving researchers at Karolinska Institutet in Stockholm has now found that a much lower dose than the standard produces a good effect with fewer adverse reactions in women who have yet to enter the menopause. The study, which has been published in the Journal of Clinical Oncology, can play a significant role in the treatment.

Researchers at Karolinska Institutet show how a certain type of immune cells, macrophages, can be recruited into breast cancer tumors, where they are reprogrammed to support and drive tumor growth. In a study published in the scientific journal PNAS, they describe that low levels of the tumor suppressor protein TAp73 lead to hyperactivation of NFkB signaling and an inflammatory condition in breast cancer as well as secretion of molecules that recruit tumor-promoting macrophages into the tumor.

KI is participating in a new EU project about using Real World Data (RWD) to improve post treatment in breast cancer, as well as shaping guidelines and best practices for researchers, public health and regulatory bodies throughout Europe to facilitate wider adaption of RWD in research and clinical practice.

One woman in eight develops breast cancer during her lifetime in the Western world and although mammography screening reduces mortality by early detection, approximately one fourth of the women who develop breast cancer are diagnosed within two years after a negative screen.

Hi there Maria Fjell, researcher at the Department of Neurobiology, Care Sciences and Society, Karolinska Institutet who recently defended her thesis “Supportive care for patients with breast cancer by using an interactive app during neoadjuvant chemotherapy – a Randomized Controlled Trial”. What’s the main focus of the thesis?

In her thesis, Shadi Azam studied the association between established breast cancer risk factors with mammographic density change over time and mammographic microcalcifications by using data from the prospective KARMA cohort.

Women with breast cancer whose eggs or ovarian tissue were frozen had more children after their diagnosis than women who did not undergo fertility preservation using those methods before start of cancer treatment. That is according to a study by researchers at Karolinska Institutet in Sweden, published in JAMA Oncology. According to the researchers, the result highlights the importance of reproductive counseling and fertility preservation for women who are diagnosed with cancer at a young age.

A comprehensive comparison of cancer survival between the Nordic countries shows improvements for all countries over time with previously observed differences attenuated. The reasons for these improvements are likely multifactorial. Previous studies comparing cancer survival between the Nordic countries have found marked differences, with a notably poorer survival in Danish patients.

In his thesis, Emilio Ugalde Morales uses a molecular epidemiology approach to investigate the association between risk factors and aggressive breast cancer defined by tumor characteristics, intrinsic subtypes, mode of detection, and survival.

Researchers at Karolinska Institutet and Karolinska University Hospital in Sweden have compared the ability of three different artificial intelligence (AI) algorithms to identify breast cancer based on previously taken mammograms. The best algorithm proved to be as accurate as the average radiologist. The results, published in JAMA Oncology, may lead the way in reorganising breast cancer screening for the future.

Some mammographic features - breast density, microcalcifications, and masses - are associated with increased breast cancer risk

Two new research programmes focusing on AI and bioelectronic medicine, for application in the areas of breast cancer and inflammatory disease, respectively, have been adopted at MedTechLabs. An interdisciplinary centre run by KTH, Karolinska Institutet and the Stockholm Region.

On Tuesday December 10, Gabriel Isheden will defend his thesis Statistical models of breast cancer tumour growth and spread".

Cells exposed to cancer-driving mutations respond by triggering a stress reaction called cellular senescence, which halts cell proliferation and thereby constitutes the major protective barrier to cancer. Researchers at Karolinska Institutet have now discovered a previously unknown signaling pathway that controls cellular senescence in breast cancer.

Researchers at Karolinska Institutet in Sweden have investigated the long-term effect of hormonal therapy in women with the most common types of hormone-sensitive breast cancer. The results, presented in the journal JAMA Oncology, show that the treatment has a protective effect against distant metastatic cancer for both so-called Luminal A and Luminal B breast cancer subtypes, and a long-term effect for women diagnosed with Luminal A cancer.

Carina Strell and colleagues in the Arne Östman research group has published an article in Journal of the National Cancer Institute investigating mechanisms controlling fibroblast functions in ductal breast carcinoma in situ (DCIS).

In the present study Elin Sjöberg and colleagues in the Arne Östman research group have identified that cancer associated fibroblast (CAF)-produced CXCL14 re-activates a developmental program that promote migration and invasion of cancer cells, leading to increased formation of lung metastasis in mice. They also identified a novel CXCL14-signaling component, ACKR2, which is important for the tumor-promoting effects of CXCL14.

In a new study, led by Professor Janne Lehtiö (SciLifeLab/Karolinska Institutet), researchers from SciLifeLab, University of Oslo, and MD Anderson Cancer Center have generated a detailed map of protein levels in breast tumors. The proteome complements the previously known DNA and RNA picture of breast cancer and sheds light on how different mutations give rise to changes on the protein level.

Nick Tobin, Arian Lundberg and colleagues have shown the broad clinical utility of the Recurrence Score and PAM50 breast cancer gene signatures in two papers published simultaneously in Clinical Cancer Research.